Clinical Trials Logo
  1. Home
  2. Hyperuricemia
  3. NCT00955981

Gout Dose Response Study

Hyperuricemia Clinical Trial

Official title:
Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout

Clinical Trial Summary

To compare the proportion of subjects whose serum urate (sUA) level is < 6.0 mg/dL after 28 days of dosing by treatment group.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00955981
Study type Interventional
Source Ardea Biosciences, Inc.
Contact
Status Completed
Phase Phase 2
Start date July 2009
Completion date September 2011
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05434858 - Imagery as Biomarker of Gout N/A
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Recruiting NCT05504083 - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients Phase 2
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Completed NCT00288158 - Primary Prevention of Hypertension in Obese Adolescents Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT04236219 - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT06084585 - The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Not yet recruiting NCT04586803 - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers Phase 1
Completed NCT02959918 - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid Phase 2
Not yet recruiting NCT02944214 - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients N/A
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2
Active, not recruiting NCT01021241 - Safety and Efficacy Study of Intravenous Uricase-PEG 20 Phase 1
Completed NCT00756964 - Lowering Serum Uric Acid to Prevent Acute Kidney Injury Phase 2
Terminated NCT00607152 - Rasburicase (Fasturtec) Registration Trial Phase 3